NO320494B1 - Renset protein med antagonistisk aktivitet mot minst en av forbindelsene valgt fra gruppen bestaende av interleukin-1-a og interleikun-1-b, isolert DNA sekvens, vektor, vertscelle, og fremgangsmater og anvendelser derav. - Google Patents
Renset protein med antagonistisk aktivitet mot minst en av forbindelsene valgt fra gruppen bestaende av interleukin-1-a og interleikun-1-b, isolert DNA sekvens, vektor, vertscelle, og fremgangsmater og anvendelser derav. Download PDFInfo
- Publication number
- NO320494B1 NO320494B1 NO19971624A NO971624A NO320494B1 NO 320494 B1 NO320494 B1 NO 320494B1 NO 19971624 A NO19971624 A NO 19971624A NO 971624 A NO971624 A NO 971624A NO 320494 B1 NO320494 B1 NO 320494B1
- Authority
- NO
- Norway
- Prior art keywords
- lra
- icel
- sequence
- interleukin
- dna sequence
- Prior art date
Links
- 108091028043 Nucleic acid sequence Proteins 0.000 title claims abstract description 22
- 238000000034 method Methods 0.000 title claims abstract description 21
- 108090000623 proteins and genes Proteins 0.000 title claims description 37
- 102000004169 proteins and genes Human genes 0.000 title claims description 32
- 239000013598 vector Substances 0.000 title claims description 5
- 230000003042 antagnostic effect Effects 0.000 title claims description 4
- 150000001875 compounds Chemical class 0.000 title claims description 4
- 108010002352 Interleukin-1 Proteins 0.000 claims abstract description 30
- 239000005557 antagonist Substances 0.000 claims abstract description 23
- 230000007170 pathology Effects 0.000 claims abstract description 13
- 108020004511 Recombinant DNA Proteins 0.000 claims abstract description 6
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 27
- 208000030507 AIDS Diseases 0.000 claims description 7
- 108020004414 DNA Proteins 0.000 claims description 7
- 102000015696 Interleukins Human genes 0.000 claims description 7
- 108010063738 Interleukins Proteins 0.000 claims description 7
- 230000005764 inhibitory process Effects 0.000 claims description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
- 206010000890 Acute myelomonocytic leukaemia Diseases 0.000 claims description 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 4
- 206010040070 Septic Shock Diseases 0.000 claims description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 4
- 230000008105 immune reaction Effects 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 230000036303 septic shock Effects 0.000 claims description 4
- 238000002054 transplantation Methods 0.000 claims description 4
- 230000001363 autoimmune Effects 0.000 claims description 3
- 238000005516 engineering process Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 208000033835 Myelomonocytic Acute Leukemia Diseases 0.000 claims description 2
- 208000011912 acute myelomonocytic leukemia M4 Diseases 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 238000002955 isolation Methods 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 102000000589 Interleukin-1 Human genes 0.000 abstract description 28
- 230000000069 prophylactic effect Effects 0.000 abstract description 4
- 230000018276 interleukin-1 production Effects 0.000 abstract description 2
- 229940124084 Interleukin 1 antagonist Drugs 0.000 abstract 1
- 102000003777 Interleukin-1 beta Human genes 0.000 abstract 1
- 108090000193 Interleukin-1 beta Proteins 0.000 abstract 1
- 102000004125 Interleukin-1alpha Human genes 0.000 abstract 1
- 108010082786 Interleukin-1alpha Proteins 0.000 abstract 1
- 239000003407 interleukin 1 receptor blocking agent Substances 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 description 23
- 235000018102 proteins Nutrition 0.000 description 22
- 108091034117 Oligonucleotide Proteins 0.000 description 14
- 235000001014 amino acid Nutrition 0.000 description 14
- 238000003757 reverse transcription PCR Methods 0.000 description 13
- 210000002889 endothelial cell Anatomy 0.000 description 12
- 230000000694 effects Effects 0.000 description 10
- 210000001616 monocyte Anatomy 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 239000002773 nucleotide Substances 0.000 description 9
- 125000003729 nucleotide group Chemical group 0.000 description 9
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 8
- 230000003321 amplification Effects 0.000 description 8
- 210000002950 fibroblast Anatomy 0.000 description 8
- 238000003199 nucleic acid amplification method Methods 0.000 description 8
- 239000013592 cell lysate Substances 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 108010024212 E-Selectin Proteins 0.000 description 6
- 102100023471 E-selectin Human genes 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 102100039065 Interleukin-1 beta Human genes 0.000 description 2
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 2
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 230000001270 agonistic effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 102000009634 interleukin-1 receptor antagonist activity proteins Human genes 0.000 description 2
- 108040001669 interleukin-1 receptor antagonist activity proteins Proteins 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 108091027963 non-coding RNA Proteins 0.000 description 2
- 102000042567 non-coding RNA Human genes 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 150000004633 phorbol derivatives Chemical class 0.000 description 2
- 239000002644 phorbol ester Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000004983 pleiotropic effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000013615 primer Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- 235000011178 triphosphate Nutrition 0.000 description 2
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000800488 Homo sapiens T-cell leukemia homeobox protein 1 Proteins 0.000 description 1
- 102000039996 IL-1 family Human genes 0.000 description 1
- 108091069196 IL-1 family Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 238000011050 LAL assay Methods 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 102100033111 T-cell leukemia homeobox protein 1 Human genes 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- GEHJBWKLJVFKPS-UHFFFAOYSA-N bromochloroacetic acid Chemical compound OC(=O)C(Cl)Br GEHJBWKLJVFKPS-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000002230 centromere Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000003963 intermediate filament Anatomy 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 1
- 238000011206 morphological examination Methods 0.000 description 1
- 230000001452 natriuretic effect Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229940079938 nitrocellulose Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physics & Mathematics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI942097A IT1270662B (it) | 1994-10-13 | 1994-10-13 | Antagonista della interleuchina-1 |
| PCT/EP1995/004023 WO1996012022A1 (en) | 1994-10-13 | 1995-10-12 | Intracellular isoform of the interleukin-1 receptor antagonist |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO971624D0 NO971624D0 (no) | 1997-04-09 |
| NO971624L NO971624L (no) | 1997-05-30 |
| NO320494B1 true NO320494B1 (no) | 2005-12-12 |
Family
ID=11369705
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19971624A NO320494B1 (no) | 1994-10-13 | 1997-04-09 | Renset protein med antagonistisk aktivitet mot minst en av forbindelsene valgt fra gruppen bestaende av interleukin-1-a og interleikun-1-b, isolert DNA sekvens, vektor, vertscelle, og fremgangsmater og anvendelser derav. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US5739282A (ja) |
| EP (1) | EP0786002B1 (ja) |
| JP (1) | JPH10509306A (ja) |
| KR (1) | KR100237936B1 (ja) |
| CN (2) | CN1224707C (ja) |
| AT (1) | ATE303439T1 (ja) |
| BR (1) | BR9509317A (ja) |
| CA (1) | CA2202470C (ja) |
| DE (1) | DE69534419T2 (ja) |
| EE (1) | EE03697B1 (ja) |
| ES (1) | ES2243942T3 (ja) |
| HK (2) | HK1002659A1 (ja) |
| IT (1) | IT1270662B (ja) |
| MX (1) | MX9702616A (ja) |
| NO (1) | NO320494B1 (ja) |
| PT (1) | PT786002E (ja) |
| RU (1) | RU2193064C2 (ja) |
| UA (1) | UA65522C2 (ja) |
| WO (1) | WO1996012022A1 (ja) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5075222A (en) * | 1988-05-27 | 1991-12-24 | Synergen, Inc. | Interleukin-1 inhibitors |
| US5872095A (en) * | 1990-05-01 | 1999-02-16 | Chiron Corporation | IL-1 receptor antagonists medicaments |
| WO1998018823A1 (en) * | 1996-10-31 | 1998-05-07 | Applied Research Systems Ars Holding N.V. | Ice inhibiting peptides |
| ES2312179T3 (es) * | 1996-12-06 | 2009-02-16 | Amgen Inc. | Terapia combinada que utiliza un inhibidor del il-1 para el tratamiento de enfermedades mediadas por el il-1. |
| US6294170B1 (en) | 1997-08-08 | 2001-09-25 | Amgen Inc. | Composition and method for treating inflammatory diseases |
| IL126562A0 (en) * | 1998-10-14 | 1999-08-17 | Interpharm Lab Ltd | Expression and secretion of icil-1 receptor antagonist type ii |
| US20020077276A1 (en) * | 1999-04-27 | 2002-06-20 | Fredeking Terry M. | Compositions and methods for treating hemorrhagic virus infections and other disorders |
| US7166712B2 (en) * | 2000-07-12 | 2007-01-23 | Philadelphia, Health And Education Corporation | Mammalian MDM2 binding proteins and uses thereof |
| HUE064610T2 (hu) * | 2003-12-23 | 2024-04-28 | Genentech Inc | Új anti-IL 13 antitestek és alkalmazásaik |
| EP1896053B1 (en) | 2004-07-06 | 2018-10-31 | ZymoGenetics, Inc. | Pharmaceutical composition comprising fgf18 and il-1 antagonist and method of use |
| EP2217258B1 (en) | 2007-11-14 | 2014-03-26 | General Regeneratives Limited | Use of interleukin-1 receptor antagonist as a myeloprotective agent |
| CN101690801B (zh) | 2009-10-26 | 2012-08-01 | 上海交通大学 | 白细胞介素-1受体拮抗剂的用途及其药物组合物 |
| ES2600616T3 (es) | 2011-03-14 | 2017-02-10 | Phlogo Aps | Antagonistas del receptor de la interleucina-1 |
| WO2013184938A2 (en) | 2012-06-08 | 2013-12-12 | Alkermes. Inc. | Fusion polypeptides comprising mucin-domain polypeptide linkers |
| WO2015191783A2 (en) | 2014-06-10 | 2015-12-17 | Abbvie Inc. | Biomarkers for inflammatory disease and methods of using same |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0148009B1 (ko) * | 1988-05-27 | 1998-08-01 | 그래고리 비. 아보트 | 인터루킨-1 억제제 |
| HUT64582A (en) * | 1989-11-29 | 1994-01-28 | Synergen Inc | Method for producing recombinant human interleukin-1 inhibitor |
| AU649245B2 (en) * | 1990-04-02 | 1994-05-19 | Amgen, Inc. | Methods for treating interleukin-1 mediated diseases |
| WO1991017184A1 (en) * | 1990-04-27 | 1991-11-14 | The Upjohn Company | Modified interleukin-1 inhibitors |
| JPH05506986A (ja) * | 1990-05-01 | 1993-10-14 | カイロン コーポレイション | インターロイキン―１拮抗物質及びその利用 |
-
1994
- 1994-10-13 IT ITMI942097A patent/IT1270662B/it active IP Right Grant
-
1995
- 1995-06-07 US US08/476,860 patent/US5739282A/en not_active Expired - Fee Related
- 1995-10-12 DE DE69534419T patent/DE69534419T2/de not_active Expired - Fee Related
- 1995-10-12 PT PT95936482T patent/PT786002E/pt unknown
- 1995-10-12 RU RU97107461/13A patent/RU2193064C2/ru not_active IP Right Cessation
- 1995-10-12 WO PCT/EP1995/004023 patent/WO1996012022A1/en active IP Right Grant
- 1995-10-12 ES ES95936482T patent/ES2243942T3/es not_active Expired - Lifetime
- 1995-10-12 EE EE9700090A patent/EE03697B1/xx not_active IP Right Cessation
- 1995-10-12 KR KR1019970701931A patent/KR100237936B1/ko not_active IP Right Cessation
- 1995-10-12 EP EP95936482A patent/EP0786002B1/en not_active Expired - Lifetime
- 1995-10-12 CN CNB951956647A patent/CN1224707C/zh not_active Expired - Fee Related
- 1995-10-12 CA CA002202470A patent/CA2202470C/en not_active Expired - Fee Related
- 1995-10-12 MX MX9702616A patent/MX9702616A/es not_active IP Right Cessation
- 1995-10-12 BR BR9509317A patent/BR9509317A/pt not_active Application Discontinuation
- 1995-10-12 AT AT95936482T patent/ATE303439T1/de not_active IP Right Cessation
- 1995-10-12 JP JP8512932A patent/JPH10509306A/ja active Pending
- 1995-10-12 CN CNB200510053993XA patent/CN100363053C/zh not_active Expired - Fee Related
- 1995-12-10 UA UA97052129A patent/UA65522C2/uk unknown
-
1997
- 1997-04-09 NO NO19971624A patent/NO320494B1/no not_active IP Right Cessation
-
1998
- 1998-02-27 HK HK98101565A patent/HK1002659A1/xx not_active IP Right Cessation
-
2006
- 2006-03-22 HK HK06103612A patent/HK1081124A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| RU2193064C2 (ru) | 2002-11-20 |
| ITMI942097A1 (it) | 1996-04-13 |
| AU701471B2 (en) | 1999-01-28 |
| HK1081124A1 (en) | 2006-05-12 |
| US5739282A (en) | 1998-04-14 |
| NO971624D0 (no) | 1997-04-09 |
| CN1679919A (zh) | 2005-10-12 |
| HK1002659A1 (en) | 1998-09-11 |
| MX9702616A (es) | 1998-04-30 |
| ITMI942097A0 (it) | 1994-10-13 |
| CN1224707C (zh) | 2005-10-26 |
| BR9509317A (pt) | 1997-10-14 |
| CN100363053C (zh) | 2008-01-23 |
| WO1996012022A1 (en) | 1996-04-25 |
| EE03697B1 (et) | 2002-04-15 |
| EP0786002B1 (en) | 2005-08-31 |
| NO971624L (no) | 1997-05-30 |
| CA2202470A1 (en) | 1996-04-25 |
| CN1161058A (zh) | 1997-10-01 |
| JPH10509306A (ja) | 1998-09-14 |
| KR100237936B1 (ko) | 2000-01-15 |
| KR970706391A (ko) | 1997-11-03 |
| ATE303439T1 (de) | 2005-09-15 |
| EP0786002A1 (en) | 1997-07-30 |
| DE69534419T2 (de) | 2006-06-14 |
| IT1270662B (it) | 1997-05-07 |
| CA2202470C (en) | 2008-09-16 |
| AU3841795A (en) | 1996-05-06 |
| ES2243942T3 (es) | 2005-12-01 |
| UA65522C2 (en) | 2004-04-15 |
| DE69534419D1 (de) | 2005-10-06 |
| EE9700090A (et) | 1997-10-15 |
| PT786002E (pt) | 2005-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Offner et al. | Recombinant human β-galactoside binding lectin suppresses clinical and histological signs of experimental autoimmune encephalomyelitis | |
| Cruikshank et al. | Interleukin‐16 | |
| NO320494B1 (no) | Renset protein med antagonistisk aktivitet mot minst en av forbindelsene valgt fra gruppen bestaende av interleukin-1-a og interleikun-1-b, isolert DNA sekvens, vektor, vertscelle, og fremgangsmater og anvendelser derav. | |
| US20030171280A1 (en) | Compositions and methods for modulation of immune responses | |
| NZ260843A (en) | P40 homodimer (two associated p40 subunits) of interleukin 12, its preparation and compositions thereof | |
| JP2002516103A (ja) | インターロイキン２１およびインターロイキン２２ | |
| JP2001510035A (ja) | インターロイキン−２０ | |
| US5981713A (en) | Antibodies to intereleukin-1 antagonists | |
| EA005581B1 (ru) | ПОЛИПЕПТИДЫ ЦИТОКИНА Zcyto10 ЧЕЛОВЕКА И МЫШИ, КОДИРУЮЩИЕ ИХ ПОЛИНУКЛЕОТИДЫ И АНТИТЕЛА К УКАЗАННЫМ ПОЛИПЕПТИДАМ | |
| JP2002505582A (ja) | Ｌａｇ−３スプライス変異体 | |
| Cruikshank et al. | Signaling and functional properties of interleukin-16 | |
| US20060275316A1 (en) | Modulation of cxcr4 and related methods and compositions | |
| WO1992012175A1 (en) | Cytokine-induced protein, tsg-6, dna coding therefor and uses thereof | |
| CN106279423B (zh) | Slit2D2-HSA融合蛋白及其在抗肿瘤中的应用 | |
| US6180602B1 (en) | Human novel cDNA, TGF-beta superfamily protein encoded thereby and the use of immunosuppressive agent | |
| EP0869812B1 (en) | C-c chemokines that inhibit retrovirus infection | |
| PL204231B1 (pl) | Zastosowanie mutanta chemokiny CC, kompozycja farmaceutyczna do leczenia stwardnienia rozsianego, skrócona i zmutowana ludzka RANTES i sposób jej wytwarzania, cząsteczka DNA i zawierający ją wektor ekspresyjny oraz komórka gospodarza | |
| WO2011038689A1 (zh) | 人类新细胞因子VSTM1-v2及其应用 | |
| US5837495A (en) | DNA encoding interleukin-1 antagonist | |
| AU701471C (en) | Interleukin-1 antagonist | |
| WO1998024817A1 (fr) | Nouvel adn, nouvelle proteine et nouvel anticorps | |
| JP5176099B2 (ja) | ＨＬＡ−Ａ１１拘束性Ｔａｘ抗腫瘍エピトープ | |
| Stiemer et al. | A common epitope on human tumor necrosis factor alpha and the autoantigen ‘S-antigen/arrestin’induces TNF-α production | |
| WO2004092373A1 (ja) | Ｈｔｌｖ－ｉ特異的ｃｔｌ誘導活性ペプチド | |
| US6673893B1 (en) | Leukocyte derived growth factor 2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CREP | Change of representative |
Representative=s name: ONSAGERS AS, POSTBOKS 6963 ST OLAVS PLASS, 0130 OS |
|
| CREP | Change of representative |
Representative=s name: ZACCO NORWAY AS, POSTBOKS 2003 VIKA, 0125 OSLO, NO |
|
| MM1K | Lapsed by not paying the annual fees |